Symbols

VRTX

Vertex Pharmaceuticals·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 0

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About VRTX

Vertex Pharmaceuticals Incorporated

A company that develops therapies for the treatment of cystic fibrosis

Industry

Biological Technology

Established Date

Listing Date

07/24/1991

Exchange

NASDAQ Stock Exchange

Full-time Employees

6,400

Fiscal Year Ends

12-31

Website

www.vrtx.com

Security Type

Common stock

Office address

50 Northern Avenue, Boston, Massachusetts 02210

Business

Develop and create transformative drugs

Introduction

Incorporated in Massachusetts in 1989, Vertex Pharmaceuticals Incorporated is a global biotechnology company dedicated to scientific innovation to create transformative medicines for individuals with serious diseases, especially in the specialty market. The company has developed approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain. The company continues to innovate and advance next-generation clinical and research projects across a variety of serious diseases, including IgA nephropathy and type 1 diabetes.

Company Financials

EPS

VRTX has released its 2025 Q4 earnings. EPS was reported at 5.03, versus the expected 5.08, missing expectations. The chart below visualizes how VRTX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

VRTX has released its 2025 Q4 earnings report, with revenue of 3.19B, reflecting a YoY change of 9.55%, and net profit of 1.19B, showing a YoY change of 30.46%. The Sankey diagram below clearly presents VRTX's revenue sources and cost distribution.